Browse drugs

…d chelator and radiolabeled with Al 18F to generate radiotracer 18F-G1. Its imaging and pharmacokinetic properties were compared with …

…of the vascular endothelium in a potential protective effect of glucosamine use on many health outcomes, whether this relationship is causa…

… who had received a course of SC antibiotics (Tazocin (86%) and Ertapenem (14%)) were included. Only 1 of 7 patients (14%) experienced lo…

…yes of 148 patients diagnosed with NIU were treated with either originator adalimumab (n=193, 74.23%) or a biosimilar (n=67, 25.77%). Median follow-u…

…rine model of hematologic malignancy, CAR-T cells utilizing the rVAR2 catenane (AXVB) as a targeting module exhibited superior antitu…

…sed to treat viral infections, pain or allergies and that using antibiotics without consulting a medical professional is not safe. During p…

…to 2022 (6.8% vs 19.3%; aRR 2.80 (95% CI 2.52 to 3.11)) whereas muscle relaxant use did not change (14.5% vs 13.5%; aRR 0.93 (95% CI 0.85 to 1.…

…ed so far. In Part A, 9 patients in three dose cohorts received ILKN421H. All patients demonstrated high and prolonged plasma level of I…

… plus ramucirumab and paclitaxel); and b) first-line (1L) TNBC (HCB101 plus toripalimab and nab-paclitaxel). Primary endpoints were sa…

…he only grade 3 AE observed, in 1 subject receiving 70 μg/kg of JL18008. The dose range of 20 to 70 μg/kg is anticipated to be the effe…

…-specific CAR-T cells, generated in vivo from human PBMCs using AVO-100, control Raji tumor growth (A), improve mouse survival (B) and …

…-PD1. Hhep was only present in tumors of mice treated with both Hhep and anti-PD1. Dual treatment resulted in a significant increase…